Toulouse Cedex 9

• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor
• NEOADJUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MU … Recruiting
  2024-519113-59-00 4 2024-11-20 Hepatocellular carcinoma
• Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial Recruiting
  2024-514799-42-00 4 2024-11-05 IDIOPATHIC PULMONARY FIBROSIS
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al … Recruiting
  2024-517004-11-00 5 2024-10-22 Chronic pulmonary aspergillosis
• A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d … Recruiting
  2022-502289-25-00 5 2024-08-28 Moderate to Severe Active Systemic Lupus Erythematosus
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant … Recruiting
  2023-505678-14-00 4 2024-08-19 Ulcerative Colitis
• A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime … Recruiting
  2023-509807-34-00 4 2024-08-12 Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementi
• Comparison of the efficacy of standard treatment associated with phage therapy versus standard treatment plus placebo for diabetic foot ulce … Recruiting
  2022-500541-24-00 9 2024-07-02 Diabetic foot
• Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis With Polyangiitis Recruiting
  2023-504245-32-00 4 2024-06-06 Eosinophilic granulomatosis with polyangiitis (EGPA)
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 Crohn's disease
• Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international … Recruiting
  2023-508153-12-00 5 2024-03-26 Hospital-acquired pneumonia
• A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants with Eosinophilic Gastritis with or without Eosinophilic Duod … Recruiting
  2022-500795-62-00 4 2024-03-25 Eosinophilic gastritis
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Ato … Recruiting
  2022-501478-21-00 5 2024-03-15 Atopic Dermatitis Eczema
• A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies Recruiting
  2022-503136-13-00 1 2024-02-29 various B-cell malignancies
• A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea … Recruiting
  2022-501980-42-00 5 2023-12-21 Anemia associated with Chronic Kidney Disease
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome Recruiting
  2023-505140-19-00 5 2023-07-31 Childhood Idiopathic Nephrotic Syndrome
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of … Recruiting
  2023-504254-35-00 7 2023-06-20 Unresectable locally advanced or metastatic solid tumors: • Clear cell
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting
  2023-509810-13-00 4 2023-05-13 Acute Lymphoblastic Leukemia (ALL)
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with A … Recruiting
  2023-508349-42-00 3 2022-10-18 Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 k
• BIVV020 (SAR445088) in prevention and treatment of antibody-mediated rejection (AMR) Recruiting
  2023-509936-25-00 4 2022-06-09 Transplant Rejection
• Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting
  2022-501893-21-00 4 2022-05-03 Acute myocardial infarction

Showing 121–144 of 893 trials